Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.82 - $24.75
Previous CloseN/A
Volume220.82K
Average Volume (3M)132.20K
Market Cap
$47.13M
Enterprise Value$170.92M
Total Cash (Recent Filing)$62.48M
Total Debt (Recent Filing)$194.52M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 01, 2025EPS Estimate
-4.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.34
Shares Outstanding8,416,004
10 Day Avg. Volume110,482
30 Day Avg. Volume132,204
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.37
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap3.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.23
Enterprise Value/Ebitda-4.43
Forecast
1Y Price Target
$54.00Price Target Upside1141.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Karyopharm Therapeutics News
PremiumCompany Announcements
Karyopharm’s Earnings Call: Growth Amid Financial Challenges
---
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalXpovio previously received FDA Fast Track Designation for the treatment of patients with myelofibrosis.
Revenue PotentialKaryopharm estimates a peak revenue opportunity of $1 billion for Xpovio in myelofibrosis.
Bears Say
Financial PerformanceKaryopharm is decreasing FY25 revenue estimate to $144.3M from $152.3M.
Sales ChallengesXpovio net product revenue in 2024 was impacted by higher gross-to-net adjustments, driven primarily by increased 340B discounts and Medicare rebates.
---
Ownership Overview
2.44% Insiders
9.29% Mutual Funds
20.38% Other Institutional Investors
60.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $4.82 and its highest was $24.75 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $47.13M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 34 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Feb 19, 2025. The company reported -$3.6 earnings per share for the quarter, beating the consensus estimate of -$3.921 by $0.321.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -4.42.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 8,416,004 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$3.6 in its last earnings report, beating expectations of -$3.921. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
---
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (1141.38% Upside)
$54.00 (1141.38% Upside)
Hedge Fund Trend
Decreased
By 4.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 13.1%
Last 30 Days ▼ 13.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.73%
12-Months-Change
Fundamentals
Return on Equity
41.08%
Trailing 12-Months
Asset Growth
-31.62%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
---
KPTI Company Deck
---
KPTI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in XPOVIO net product revenue and significant progress in clinical trials for myelofibrosis and endometrial cancer. However, challenges included a decrease in total revenue from licensing agreements, an increased gross-to-net discount, and a reduced cash position, signaling potential financial concerns. The overall sentiment is balanced with notable achievements offset by financial challenges.Read More>---
KPTI Stock 12 Month Forecast
Average Price Target
$54.00
▲(1141.38% Upside)
Technical Analysis
Neurocrine
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Blueprint Medicines
―
Best Analysts Covering KPTI
1 Year
1 Year Success Rate
2/28 ratings generated profit
1 Year Average Return
-54.52%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -54.52% per trade.
---